Brief: Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease
27/10/2025 13:16
Oct 27 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS LAUNCHES VA-BACKED STUDY OF NOVEL GDNF WEIGHT LOSS THERAPY TARGETING OBESITY AND FATTY LIVER DISEASE HOTH THERAPEUTICS INC - INITIAL RESULTS EXPECTED Q1 2026 Source text: ID:nPn5FdV4Ma Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology